As the success stories of VitroGel® keep growing in different research areas, we continue to collect and highlight some recent publications on this xeno-free tunable hydrogel system. Here are the research highlights in September 2019.
Trk-ing down castration-resistant prostate cancer: 3D cancer-derived organoids introduce TrkA as a promising new biomarker and target for an aggressive form of prostate cancer
Getting to the root of the problem: The biocompatible and injectable VitroGel® hydrogel culture system enhances odontogenic differentiation in vivo AMD pulp-dentin regeneration, which has the potential for chair-side regenerative endodontic procedures
Breaking the (cell) cycle: Introducing CDK9 as a prognostic biomarker and therapeutic target in synovial sarcomas. Repressing CDK9 blocks cell spheroid formation in 3D culture and delays growth of synovial sarcoma cells
A novel BST-based analog, B49, may prevent breast cancer metastasis by disrupting BST-2 dimerization:
VitroGel help to unravel the role and mechanism of action of BST-2 in breast cancer growth and metastasis and introduce a putative new therapy
VitroGel is a family of ready-to-use, xeno-free hydrogel system that enables 3D cell culture in 20 minutes. The tunable features in gel strength and functional ligands lead to multiple applications. Cells cultured in this system can be easily harvested out. The hydrogel is injectable for in vivo studies.